
ABOUT ROCHE CUSTOMBIOTECH
Roche CustomBiotech enables the healthcare industry to bring state-of-the-art diagnostics and treatments to those in need, by providing reliable, tailored and high-quality products and raw-materials to biotech and diagnostics companies.
We have merged our innovative technologies, unique knowledge, and decades of experience under one roof in Penzberg, Germany.
Leveraging the unique know-how of Roche Diagnostics and Roche Pharmaceuticals, Roche CustomBiotech has comprehensive product portfolios of differentiated solutions that drive real value for your bioprocess. Learn more about our high-quality raw materials for mRNA and protein glycosylation, as well as the Cedex analyzer family of cell culture analysis instrumentation, and rapid PCR-based QC testing kits. Contact us to discuss how we can support your goals.
CONTACT INFORMATION
Roche CustomBiotech
9115 Hague Road
Indianapolis, IN 46250
UNITED STATES
Phone: 1-800-428-5433
Contact: Laura Clayton
FEATURED ARTICLES
-
Learn about the problem of immunogenicity of mRNA, modified ribonucleotides, modified mRNA via in vitro transcription production, and choosing fit-for-purpose modified ribonucleotides.
-
Learn about tools to optimize the IVT reaction for enhanced mRNA yield, along with how factors such as magnesium ion and nucleotide concentrations significantly impact that IVT reaction performance.
-
Explore the advantages of mRNA technology, the process steps of large-scale mRNA production, and the effect of common contaminants on mRNA manufacturing.
-
Learn what some practical considerations are for implementing NAT-based methods, where concrete recommendations are necessary, and how guidelines can remain relevant for new medicinal products.
-
Learn about a solution for streamlining workflow in novel biologics while collecting quality data, by combining single-use microbioreactors with advanced automation and analytical platforms.
-
In this assessment of the in vitro glycoengineering technology we determine if it is suitable for the development, manufacturing, and analysis of therapeutic proteins.
VIDEOS
-
Expert panelists provide commentary on specific steps considered to be challenging in mRNA therapeutic development as well as new technologies in mRNA therapeutic development.
-
Novel excipients or active substances? In this segment of Risk Reduction In mRNA Therapeutic Development, we address the debate and discuss LNP-related inflammatory response concerns.
-
What challenges do you consider the most formidable in your own mRNA therapeutic development environments?
-
Learn more about LNP complexity, fragility, and other lipid nanoparticle considerations in this segment from the Bioprocess Online Live digital event Risk Reduction In mRNA Therapeutic Development.
-
Safety of mRNA vaccines and therapeutics is paramount to approval, but process dependent. Listen to this discussion which addresses safety risks and how mRNA developers are tackling the challenges.
-
In this segment from the Bioprocess Online Live digital event Risk Reduction In mRNA Therapeutic Development, hundreds of audience members tell us what forms of vaccine and therapeutics they’re developing.
-
Listen in on a discussion surrounding questions about chromatography and column-free processes in the development of mRNA vaccines and therapeutics.
-
Listen in on a discussion reviewing key drivers behind the flurry of activity in mRNA therapeutic development and begin to address the rate-limiting risks to mRNA therapeutic development.
-
Learn about a family of instruments that performs precise measurements and enables informed decisions and fast time response.
-
Learn more about how certain glycoforms can be enriched in downstream processing using discrete enzymatic reactions with clear kinetics and predictable outcomes.
-
KAPA3G HotStart DNA Polymerase is a new-generation polymerase evolved for high processivity and robustness to shorten assay reaction time and minimize sample prep time without loss in performance.
-
Learn more about CustomBiotech and what they can provide to meet your mRNA needs.